成都先导: 成都先导药物开发股份有限公司第二届董事会第二十三次会议决议公告

Core Points - Chengdu Xian Dao Pharmaceutical Development Co., Ltd. held its 23rd meeting of the second board of directors on August 26, 2025, with all 9 directors present, ensuring compliance with legal and regulatory requirements [1] - The board approved several key proposals, including the review of the 2025 semi-annual report and the special report on the use of raised funds [2][3] - The board also approved the cancellation of the supervisory board and amendments to the company's articles of association, which will be submitted for shareholder approval [2][3] - The board nominated candidates for the third board of directors, including both non-independent and independent directors, pending shareholder approval [3][4] - The board reviewed and approved the semi-annual evaluation report of the 2025 quality improvement and efficiency recovery action plan [4] - The board discussed the 2025 restricted stock incentive plan and its management methods, which will also require shareholder approval [5][6] - The board proposed to authorize the board to handle matters related to the 2025 employee stock ownership plan, pending shareholder approval [8][9]